Noopept vs Semax
The distinction that mattersBoth are Russian-developed neuropeptides sold as nootropics in the West. Semax is a seven-residue ACTH fragment given intranasally; noopept is an orally active dipeptide ester. Neither has Western regulatory review.
| Noopept Limited Approval | Semax Limited Approval | |
|---|---|---|
| Evidence rating |
2/5 Limited
Evidence rating 2 out of 5: Limited
|
2/5 Limited
Evidence rating 2 out of 5: Limited
|
| Regulatory status | Registered as a prescription medicine in Russia. In the US, FDA has determined it is not a lawful dietary ingredient. Not approved in the EU or UK. | Registered in Russia for stroke, cognitive disorders and optic nerve conditions. Not approved in the US, EU or UK. |
| Category | Cognitive & Neurological | Cognitive & Neurological |
| Drug class | Dipeptide-derived nootropic — a proline-containing dipeptide ethyl ester | Synthetic heptapeptide analog of ACTH (4-10) with no corticotropic activity |
| Route | Oral or sublingual | Intranasal (primary), subcutaneous |
| Half-life | ~16–30 minutes (active metabolite cycloprolylglycine persists longer) | Minutes systemically; central effects outlast plasma levels |
| Studied in | Russian randomized trials in mild cognitive impairment of vascular and post-traumatic origin; extensive Russian preclinical work. | Russian clinical trials in ischemic stroke, cognitive impairment, optic nerve atrophy and ADHD; extensive Russian preclinical neuroprotection work. |
| Who should avoid it |
|
|
| Legal status | Prescription medicine in Russia. Not a lawful dietary supplement in the US. Unapproved in the EU and UK. | Prescription medicine in Russia. Unapproved elsewhere; import for personal use occupies a legal grey area. |
Benefits — Noopept
- Reported cognitive benefit in mild impairment
Russian randomized trials described improvement in cognitive and affective symptoms in vascular and post-traumatic cognitive impairment.
- Neurotrophin upregulation
Documented increases in hippocampal BDNF and NGF expression in animal models.
- Active at low doses
Roughly a thousandfold more potent by weight than piracetam.
- Anxiolytic component reported
Russian studies describe reduced anxiety and irritability alongside cognitive effects.
Benefits — Semax
- Neuroprotection in stroke models
Consistent reduction in infarct volume and improved functional recovery in animal ischemia models, supported by Russian clinical use.
- BDNF upregulation
Documented increases in brain-derived neurotrophic factor expression, a plausible substrate for cognitive effects.
- Reported attention and memory effects
Russian studies and extensive user reports describe improved focus and working memory; not replicated under Western trial conditions.
- No corticotropic activity
Unlike ACTH itself, it does not stimulate cortisol release — an important safety feature.
- Good short-term tolerability
Decades of Russian clinical use without major safety signals reported.
Risks & cons — Noopept
- Not a lawful supplement in the US
FDA has stated it does not meet the dietary ingredient definition, making its sale as a supplement unlawful — a fact most vendors omit.
- Evidence base not independently replicated
No Western randomized trials exist. Methodological standards in the source literature are inconsistent.
- Irritability, headache and sleep disruption
Commonly reported, particularly at higher doses or later in the day.
- Blood pressure elevation
Reported in some users; caution advised in hypertension.
- No long-term safety data
Chronic use has not been characterised outside Russian practice.
Risks & cons — Semax
- No Western regulatory review
Not evaluated by FDA or EMA. The evidence base has not been independently audited.
- Trial methodology concerns
Much of the supporting literature lacks blinding, adequate power, or placebo control by contemporary standards.
- Unknown long-term neurological effects
Chronically manipulating neurotrophin expression has no long-term human safety characterisation.
- Grey-market supply in the West
Purity and concentration of imported product are unverified.
- Overstimulation and irritability
Commonly reported at higher doses, along with headache and sleep disruption.
A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.